Arena Pharmaceuticals Stock Price Target and Analyst Ratings (NASDAQ:ARNA)

Analyst Price Target for ARNA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$90.36

▲ +11.25% Upside Potential

This price target is based on 14 analysts offering 12 month price targets for Arena Pharmaceuticals in the last 3 months. The average price target is $90.36, with a high forecast of $120.00 and a low forecast of $62.00. The average price target represents a 11.25% upside from the last price of $81.22.

Buy

The current consensus among 14 contributing investment analysts is to buy stock in Arena Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/30/2019

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/28/2019

0 strong buy ratings
4 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

1/26/2020

0 strong buy ratings
6 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

4/25/2020

0 strong buy ratings
9 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

7/24/2020

0 strong buy ratings
12 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

10/22/2020

0 strong buy ratings
14 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/21/2020

0 strong buy ratings
14 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/20/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
11/19/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Initiated Coverage	Outperform	$100.00	Low	i
11/19/2020	Smith Barney Citigroup	Initiated Coverage	Outperform	$100.00	Medium	i
11/10/2020	Guggenheim	Lower Price Target	Buy	$115.00 ➝ $105.00	High	i
11/10/2020	Royal Bank of Canada	Lower Price Target	Positive ➝ Outperform	$80.00 ➝ $76.00	High	i
11/10/2020	SVB Leerink	Boost Price Target	Outperform	$91.00 ➝ $92.00	High	i
11/2/2020	JPMorgan Chase & Co.	Boost Price Target		$71.00 ➝ $90.00	Medium	i
10/13/2020	Cantor Fitzgerald	Boost Price Target		$88.00 ➝ $110.00	Low	i
9/30/2020	Bank of America	Boost Price Target	Buy	$75.00 ➝ $85.00	Medium	i
9/18/2020	Citigroup	Boost Price Target	Buy	$83.00 ➝ $120.00	Medium	i
9/14/2020	JPMorgan Chase & Co.	Initiated Coverage	Overweight		High	i
8/17/2020	Guggenheim	Boost Price Target	Buy	$95.00 ➝ $115.00	Low	i
8/6/2020	HC Wainwright	Reiterated Rating	Buy	$90.00	High	i Rating by Patrick Trucchio at HC Wainwright
8/6/2020	Wells Fargo & Company	Boost Price Target	Overweight	$60.00 ➝ $78.00	Low	i
8/6/2020	SVB Leerink	Boost Price Target	Outperform	$73.00 ➝ $91.00	Low	i
8/6/2020	Needham & Company LLC	Reiterated Rating	Buy	$70.00	Low	i
7/27/2020	Citigroup	Boost Price Target	Buy	$65.00 ➝ $83.00	Medium	i
6/29/2020	HC Wainwright	Initiated Coverage	Buy	$90.00	High	i Rating by P. Trucchio at HC Wainwright
6/2/2020	Credit Suisse Group	Boost Price Target	Positive ➝ Outperform	$77.00 ➝ $87.00	Medium	i
5/18/2020	Jefferies Financial Group	Initiated Coverage	Buy	$62.00	High	i
5/8/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$56.00 ➝ $68.00	Low	i
4/14/2020	Needham & Company LLC	Reiterated Rating	Buy	$70.00	High	i
3/31/2020	Guggenheim	Initiated Coverage	Buy	$95.00	Low	i
3/26/2020	Bank of America	Upgrade	Neutral ➝ Buy	$47.00 ➝ $56.00	High	i
2/27/2020	Cantor Fitzgerald	Reiterated Rating	Overweight	$62.00 ➝ $56.00	High	i
1/31/2020	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$58.00	High	i
1/27/2020	Royal Bank of Canada	Reiterated Rating	Buy	$83.00	Medium	i
11/14/2019	Wood & Company	Reiterated Rating	Sell		Medium	i
11/13/2019	Bank of America	Initiated Coverage	Neutral	$51.00	Low	i
8/11/2019	Royal Bank of Canada	Reiterated Rating	Buy	$79.00	High	i
5/8/2019	Cantor Fitzgerald	Reiterated Rating	Buy		High	i Rating by A. Young at Cantor Fitzgerald
4/3/2019	Credit Suisse Group	Boost Price Target	Outperform ➝ Outperform	$63.00 ➝ $77.00	High	i
2/26/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$62.00	High	i Rating by A. Young at Cantor Fitzgerald
1/28/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$62.00	Low	i Rating by A. Young at Cantor Fitzgerald
12/13/2018	Berenberg Bank	Initiated Coverage	Buy ➝ Buy	$55.00	Low	i
11/23/2018	Cantor Fitzgerald	Reiterated Rating	Overweight		High	i Rating by A. Young at Cantor Fitzgerald
11/19/2018	Credit Suisse Group	Boost Price Target	Outperform ➝ Outperform	$56.00 ➝ $61.00	Low	i
11/16/2018	Royal Bank of Canada	Boost Price Target	Outperform	$70.00	Low	i
11/15/2018	Needham & Company LLC	Set Price Target	Buy	$60.00	High	i Rating by Alan Carr at Needham & Company LLC
11/15/2018	Cantor Fitzgerald	Set Price Target	Buy	$65.00	Low	i Rating by William Tanner at Cantor Fitzgerald
11/7/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$65.00	High	i Rating by William Tanner at Cantor Fitzgerald
9/24/2018	Cantor Fitzgerald	Set Price Target	Buy	$65.00	High	i Rating by William Tanner at Cantor Fitzgerald
8/7/2018	Credit Suisse Group	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $56.00	High	i
5/31/2018	Royal Bank of Canada	Initiated Coverage	Outperform	$65.00	Medium	i
3/21/2018	Citigroup	Reiterated Rating	Positive ➝ Buy	$62.00	High	i
3/20/2018	JMP Securities	Boost Price Target	Mkt Outperform ➝ Outperform	$63.00 ➝ $79.00	High	i
3/20/2018	Wells Fargo & Company	Lower Price Target	Positive ➝ Outperform	$53.00 ➝ $60.00	High	i
3/20/2018	Needham & Company LLC	Upgrade	Hold ➝ Buy	$30.89 ➝ $60.00	High	i
3/14/2018	Needham & Company LLC	Reiterated Rating	Hold		High	i
2/27/2018	Citigroup	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $55.00	High	i
2/20/2018	JMP Securities	Boost Price Target	Outperform	$36.00 ➝ $63.00	Low	i
1/17/2018	Credit Suisse Group	Initiated Coverage	Outperform ➝ Outperform	$44.00	Low	i
1/17/2018	SVB Leerink	Reiterated Rating	Outperform ➝ Positive	$53.00 ➝ $56.00	Low	i
1/17/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$45.00	Low	i
1/3/2018	Wells Fargo & Company	Upgrade	Market Perform ➝ Outperform		High	i
9/25/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$37.00	High	i Rating by W. Tanner at Cantor Fitzgerald
8/8/2017	Needham & Company LLC	Reiterated Rating	Hold		Medium	i
7/17/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$37.00	Low	i Rating by W. Tanner at Cantor Fitzgerald
7/12/2017	Wells Fargo & Company	Reiterated Rating	Market Perform	$15.00 ➝ $19.00	Medium	i
7/11/2017	Citigroup	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $37.00	Low	i
7/11/2017	SVB Leerink	Boost Price Target	Outperform	$47.00 ➝ $53.00	High	i Rating by J. Schwartz at SVB Leerink LLC
7/7/2017	JMP Securities	Upgrade	Market Perform ➝ Outperform	$27.00 ➝ $27.00	High	i
6/30/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$37.00	Medium	i Rating by W. Tanner at Cantor Fitzgerald
6/27/2017	Citigroup	Initiated Coverage	Buy ➝ Buy	$23.00	Medium	i
6/15/2017	Cantor Fitzgerald	Reiterated Rating	Overweight		High	i Rating by W. Tanner at Cantor Fitzgerald
5/19/2017	SVB Leerink	Initiated Coverage	Outperform ➝ Outperform	$50.00	High	i Rating by J. Schwartz at SVB Leerink LLC
3/16/2017	(FBRC)	Reiterated Rating	Outperform	$60.00	Medium	i Rating by R. Jasuja at (FBRC)
1/23/2017	(FBRC)	Reiterated Rating	Outperform		N/A	i Rating by R. Jasuja at (FBRC)
1/7/2017	Needham & Company LLC	Reiterated Rating	Hold		N/A	i
11/10/2016	Needham & Company LLC	Reiterated Rating	Hold		N/A	i
11/9/2016	(FBRC)	Reiterated Rating	Buy	$60.00	N/A	i Rating by christopher james at (FBRC)
9/15/2016	(FBRC)	Initiated Coverage	Outperform	$60.00	N/A	i Rating by C. James at (FBRC)
8/13/2016	Needham & Company LLC	Reiterated Rating	Hold		N/A	i
8/10/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i
8/8/2016	JPMorgan Chase & Co.	Reiterated Rating	Hold		N/A	i Rating by jessica fye at JPMorgan Chase & Co.
5/10/2016	Wells Fargo & Company	Reiterated Rating	Hold		N/A	i Rating by Jim Birchenough at Wells Fargo & Company
3/2/2016	Piper Jaffray Companies	Reiterated Rating	Buy		N/A	i Rating by Edward Tenthoff at Piper Jaffray Companies
3/1/2016	Royal Bank of Canada	Reiterated Rating	Sector Perform	$20.00 ➝ $15.00	N/A	i
1/27/2016	Needham & Company LLC	Reiterated Rating	Hold		N/A	i Rating by Alan Carr at Needham & Company LLC

(Data available from 1/20/2016 forward)

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, a Phase IIb/III clinical trial for Crohn's disease, and a Phase IIb clinical trial for atopic dermatitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; and APD418 that is in Phase I clinical trial for acute heart failure. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

Today's Range

Now: $81.22

$80.34

$81.75

50 Day Range

MA: $74.38

$65.31

$80.70

52 Week Range

Now: $81.22

$32.95

$90.19

Volume

466,974 shs

Average Volume

486,100 shs

Market Capitalization

$4.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Arena Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Arena Pharmaceuticals in the last year: Bank of America Co., Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Credit Suisse Group AG, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Needham & Company LLC, Royal Bank of Canada, Smith Barney Citigroup, SVB Leerink LLC, and Wells Fargo & Company.

What is the current price target for Arena Pharmaceuticals?

14 Wall Street analysts have set twelve-month price targets for Arena Pharmaceuticals in the last year. Their average twelve-month price target is $90.36, suggesting a possible upside of 12.0%. Citigroup Inc. has the highest price target set, predicting ARNA will reach $120.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $62.00 for Arena Pharmaceuticals in the next year.

What is the current consensus analyst rating for Arena Pharmaceuticals?

Arena Pharmaceuticals currently has 14 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARNA will outperform the market and that investors should add to their positions of Arena Pharmaceuticals.

What other companies compete with Arena Pharmaceuticals?

Other companies that are similar to Arena Pharmaceuticals include Amgen, Gilead Sciences, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Biogen, Alexion Pharmaceuticals, Seagen, Exact Sciences, Incyte, Alnylam Pharmaceuticals, BioMarin Pharmaceutical, Repligen, Neurocrine Biosciences, Ionis Pharmaceuticals and Novavax.

How do I contact Arena Pharmaceuticals' investor relations team?

Arena Pharmaceuticals' physical mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company's listed phone number is 858-453-7200 and its investor relations email address is ir@arenapharm.com. The official website for Arena Pharmaceuticals is www.arenapharm.com.

NASDAQ:ARNA - Arena Pharmaceuticals Stock Price Target and Predictions

Analyst Price Target for ARNA

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Arena Pharmaceuticals?

What is the current price target for Arena Pharmaceuticals?

What is the current consensus analyst rating for Arena Pharmaceuticals?

What other companies compete with Arena Pharmaceuticals?

How do I contact Arena Pharmaceuticals' investor relations team?